EGRX - Eagle Pharmaceuticals, Inc.
| Previous Close | 59.19 |
| Open | 59.47 |
| Bid | 57.64 x 900 |
| Ask | 57.67 x 1200 |
| Day's Range | 57.38 - 59.67 |
| 52 Week Range | 36.03 - 70.13 |
| Volume | 140,527 |
| Avg. Volume | 142,800 |
| Market Cap | 787.213M |
| Beta (3Y Monthly) | 1.86 |
| PE Ratio (TTM) | 19.87 |
| EPS (TTM) | 2.90 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 59.33 |
- Simply Wall St.
Does The Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Share Price Tend To Follow The Market?
If you own shares in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) then it's worth thinking about how it contributes to...
- Zacks
Insulet (PODD) Catches Eye: Stock Jumps 8.9%
Insulet (PODD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- Thomson Reuters StreetEvents
Edited Transcript of EGRX earnings conference call or presentation 8-Aug-19 12:30pm GMT
Q2 2019 Eagle Pharmaceuticals Inc Earnings Call
- Business Wire
Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
- Zacks
Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta
The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.
- Simply Wall St.
Should Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Be Your Next Stock Pick?
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...
Motley FoolEagle Pharmaceuticals Inc (EGRX) Q2 2019 Earnings Call Transcript
EGRX earnings call for the period ending June 30, 2019.
- Zacks
Eagle Pharmaceuticals (EGRX) Beats Q2 Earnings and Revenue Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 16.67% and 10.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results
-- Q2 2019 net income of $0.49 per basic and $0.48 per diluted share and adjusted non-GAAP net income of $0.86 per basic and $0.84 per diluted share --
- Business Wire
Eagle Pharmaceuticals Announces Clinical Development Plan of Innovative Product Intended to Deliver Maximum Estrogen Receptor Inhibition in Patients with Estrogen Receptor (ER)-Positive Breast Cancer
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (EGRX) today announced a clinical development plan to support the submission of a New Drug Application (NDA) for the Company’s innovative fulvestrant formulation. Fulvestrant, an estrogen receptor antagonist with no agonist properties, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced hormone-related breast cancers.
- Zacks
Earnings Preview: Eagle Pharmaceuticals (EGRX) Q2 Earnings Expected to Decline
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- MarketWatch
Park Service diverts $2.5 million in fees to pay for Trump’s July 4th celebration | Beto O’Rourke says he’s unaware of his fundraising numbers
The Washington Post reports the National Park Service is diverting nearly $2.5 million in entrance and recreation fees primarily intended to improve parks across the country to cover costs associated with President Donald Trump’s Independence Day celebration on the Mall.
- Markit
See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high and has been increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for EGRX with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting EGRX. Sentiment has worsened and traders added to their bearish short positions on June 6. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding EGRX are favorable, with net inflows of $1.29 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.
Here's Why I Think Eagle Pharmaceuticals (NASDAQ:EGRX) Might Deserve Your Attention Today
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
- Business Wire
Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
- Thomson Reuters StreetEvents
Edited Transcript of EGRX earnings conference call or presentation 7-May-19 12:30pm GMT
Q1 2019 Eagle Pharmaceuticals Inc Earnings Call
- Business Wire
Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Eagle Pharmaceuticals Inc (EGRX)
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- MoneyShow
Can Eagle Pharma Fly through its Oncology Trials
Since we began covering Eagle Pharmaceuticals (EGRX) in January 2018, the company has made progress in its portfolio of critical care and oncology treatments, but its share price has not reflected those gains. We believe there is upside potential making the stock worth reconsidering.
Motley FoolEagle Pharmaceuticals Inc (EGRX) Q1 2019 Earnings Call Transcript
EGRX earnings call for the period ending March 31, 2019.
- Zacks
Eagle Pharmaceuticals (EGRX) Beats Q1 Earnings and Revenue Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 77.19% and 12.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
